No one doubts health care in China is becoming an ever bigger story and no one will be surprised to see the Chinese authorities focus doggedly on strengthening the country’s pharmaceutical research
The small number of Chinese companies dedicated to clinical research and listed on U.S. exchanges (essentially on NASDAQ) are a poor reflection of national research occuring in the field
This is all the more reason to watch share price trends of these firms closely, as their progress will mirror governmentall policy (and financial support) to the entire sector
Dominated by BeiGene Invalid tag asset, a market cap heavyweight of $25 bn, 20.5% owned by Amgen
- High hopes in BeiGene's anti-PD-1 antibody tislelizumab, for the treatment of various solid tumor cancers is a factor in the firm's recentlly announced partnerships with Novartis -
, (Februari '21), with 111.Inc. , a leading tech-enabled healthcare platform company, (March '21) and with major pharmaceuticals firm HUTCHMED (China) (May '20), buttressing share prices and signaling an ambitious distribution strategy
Biotech company share prices are volatile because of the close correlation with experimental outcomes and no recommendation for any single company can be made
However, the performance of our selection stands out
